EyePoint Pharmaceuticals Inc (FRA:PV3B)
€ 7.932 0.038 (0.48%) Market Cap: 409.05 Mil Enterprise Value: 136.42 Mil PE Ratio: 0 PB Ratio: 1.69 GF Score: 61/100

Q1 2021 EyePoint Pharmaceuticals Inc Earnings Call Transcript

May 05, 2021 / 12:30PM GMT
Release Date Price: €8.7 (-1.14%)
Operator

Welcome to the EyePoint First Quarter 2021 Financial Results Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions) I would now like to hand the conference over to your speaker today, George Elston, Chief Financial Officer. Please go ahead.

George O. Elston
EyePoint Pharmaceuticals, Inc. - CFO & Head of Corporate Development

Thank you, and thank you all for joining us on today's conference call to discuss EyePoint Pharmaceuticals' First Quarter 2021 financial results and recent corporate developments. With me today is Nancy Lurker, President and Chief Executive Officer, Dr. Jay Duker, Chief Strategic Scientific Officer and Scott Jones, Chief Commercial Officer. Nancy, will begin with a review of recent corporate updates, Dr. Duker will then discuss pipeline developments for EYP-1901, and Scott will comment on our commercial business performance. I will close with commentary on the first quarter 2021 financial results, and we will then open the call up for your questions. Earlier this

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot